Metabolism of a new synthetic progestagen, Org 2969, in female volunteers. The distribution and excretion of radioactivity after an oral dose of the labelled drug.
The metabolism of a new synthetic progestagen, Org 2969 was studied in 4 healthy female volunteers. During the first part of the study (Phase I), the volunteers ingested 50 microgram (about 0.1 mCi) of [16-3H5Org 2969 together with 50 microgram of ethinyloestradiol as a single dose. During the second part of the study (Phase II), a 10-day pre-treatment with the same dosage of non-radioactive compound preceded the administration of the radioactive steroid. A peak level of total radioactivity, representing 3.16-5.02% of the dose given/l of serum, was achieved within 2-3 h in Phase I. During Phase II, the corresponding figures were 4.54-5.13% after 1.5-3 h. The difference was mainly due to an increase of freely-extractable steroids during Phase II. The difference can at least partly be explained by assuming a change in the kinetics of the metabolism of Org 2969 by pre-treatment with Org 2969 and ethinyloestradiol. The mean recovery of radio activity in urine and faeces was 83.0%/48.1%/34.9% (total/urine/faeces) of the total dose in Phase I and 76.1%/45.2%/30.9% during Phase II. The differences in the total excretion and in the radioactivity excreted in the faeces were significant.
D000284:Administration, Oral; D000328:Adult; D055598:Chemical Phenomena; D002621:Chemistry; D004338:Drug Combinations; D004341:Drug Evaluation; D004997:Ethinyl Estradiol / Q000008:administration & dosage; D005243:Feces / Q000032:analysis; D005260:Female; D006801:Humans; D045167:Progesterone Congeners / Q000008:administration & dosage / Q000378:metabolism* / Q000652:urine; D013997:Time Factors
D004338:Drug Combinations; D045167:Progesterone Congeners; D004997:Ethinyl Estradiol